Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study

Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study

IntroductionNipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-med...

Full description

Bibliographic Details
Main Authors: Jocelyn H. Leu, An Vermeulen, Claudia Abbes, Santiago Arroyo, William S. Denney, Leona E. Ling
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Neuroscience
Subjects:
neonatal Fc receptor
monoclonal antibodies
phase 1 clinical trial
intravenous infusions
pharmacokinetics
immunoglobulin G
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2024.1302714/full

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2024.1302714/full

Similar Items